Narrow Your Results
MSK 17-031 (SY-1425-201): A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to determine the activity of SY-1425 in relapsed/refractory acute myeloid leukemia (AML) patients, relapsed/refractory higher-risk myelodysplastic syndrome (MDS) patients (SY-1425 administered as a monotherapy or in combination with daratumumab), newly diagnosed treatment naïve AML patients who are unlikely to tolerate...
AALL1231 Lymphoblastic Leukemia and Lymphoblastic Lymphoma Study (PRO00002396)
The purpose of this research study is to compare the effects (good and bad) of two different treatment arms for T-ALL (T-lymphoblastic leukemia) and T-LLy (T-lymphoblastic lymphoma). The overall goal is to see if bortezomib will get rid of the cancer for as long as possible with as few side effects of therapy as possible.
AAML1031 Acute myeloid leukemia (AML); chemotherapy; high allelic ratio FLT3/itd (PRO00000499)
The primary objective is to compare event-free survival and overall survival in patients with de novo acute myeloid leukemia (AML), without high allelic ratio FLT3/ITD+ mutations, when randomized to standard therapy versus bortezomib/standard combination therapy.
AALL1331 B-Lymphoblastic Leukemia study (PRO00003569)
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Monoclonal antibodies, such as blinatumomab, may interfere with the ability of tumor cells to grow and spread. It is...
AALL05B1 Leukemia (ALL) Specimen Banking Study (PRO00000492)
The purpose of this study is to establish a mechanism to bank specimens of tumor cells and host germline DNA from patients with acute lymphoblastic leukemia (ALL) at first and subsequent relapse; and to make these specimens available to qualified researchers to study the biology of ALL.
ACCL0933: Acute Myeloid Leukemia Fungal Infection Study (PRO00001576)
AALL1131:Acute Lymphoblastic Leukemia (ALL)- high-risk (PRO00000497)
The study objective is to examine the 5-year disease-free survival (DFS) of children with high risk ALL and the 4-year DFS of children, adolescents and young adults with very high risk ALL.
AALL0932:Newly Diagnosed B-Lymphoblastic Leukemia or Lymphoma (PRO00000495)
Acute lymphoblastic leukemia classification
ACCL0934: Bacteremia Prevention in Acute Leukemia (PRO00001592)